Q4 FY2026 · ended Jun 30, 2026 · Revenue $42.38M, -23.1% YoY · Filed Aug 27, 2026
Lifevantage Corp (LFVN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q4 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $42.4 million and net income of $1.3 million. Free cash flow was $3.7 million. As of Jun 30, 2026 it held $14.9 million in cash and investments and $9.9 million in total debt.
Revenue
$42.38M
-23.1% vs year-ago quarter
Net income
$1.28M
-34.7% vs year-ago quarter
Operating cash flow
$4.77M
+361.0% vs year-ago quarter
Free cash flow
$3.73M
+346.7% vs year-ago quarter
EPS
$0.10
-32.3% vs year-ago quarter
Dividend per share
$0.05
+11.1% vs year-ago quarter
Shares outstanding
12.53M
-1.3% vs year-ago quarter
Net cash
$5.05M
Q4 FY2026
Operating margin
3.9%
Q4 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LFVN (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Lehi, UT
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 849146
- Former names
- LIFELINE THERAPEUTICS, INC. (until Dec 6, 2006); YAAK RIVER RESOURCES INC (until Sep 28, 2004)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
Q4 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $42.4M | $43.7M | $48.9M | $47.6M | $55.1M |
| Operating income | $1.7M | $1.7M | $487,000 | $2.3M | $2.1M |
| Net income | $1.3M | $1.4M | $276,000 | $2.2M | $2.0M |
| Diluted EPS | $0.10 | $0.11 | $0.02 | $0.17 | $0.15 |
| Operating cash flow | $4.8M | $5.0M | $2.8M | -$2.3M | $1.0M |
| Free cash flow | $3.7M | $4.0M | $1.7M | -$2.7M | $835,000 |
| Total assets | $62.1M | $62.1M | $61.2M | $61.6M | $72.0M |
| Total liabilities | $28.5M | $28.8M | $28.2M | $28.4M | $37.3M |
| Stockholders' equity | $33.6M | $33.3M | $33.0M | $33.2M | $34.6M |
| Cash and investments | $14.9M | $12.5M | $10.2M | $13.1M | $20.2M |
| Total debt | $9.9M | $10.2M | $10.7M | $11.2M | $11.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 5, 2026 | Sep 29, 2026 |
| ARS | Annual report to shareholders | Sep 18, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 27, 2026 | Aug 27, 2026 |
| 10-K | Annual report | Aug 27, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 3, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 6, 2026 | May 6, 2026 |
All 1001 Lifevantage Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.